Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Traws Pharma (TRAW) Cash & Equivalents (2016 - 2025)

Traws Pharma (TRAW) has disclosed Cash & Equivalents for 14 consecutive years, with $3.8 million as the latest value for Q4 2025.

  • For Q4 2025, Cash & Equivalents fell 82.1% year-over-year to $3.8 million; the TTM value through Dec 2025 reached $3.8 million, down 82.1%, while the annual FY2025 figure was $3.8 million, 82.1% down from the prior year.
  • Cash & Equivalents hit $3.8 million in Q4 2025 for Traws Pharma, down from $6.4 million in the prior quarter.
  • Across five years, Cash & Equivalents topped out at $59.4 million in Q3 2021 and bottomed at $3.8 million in Q4 2025.
  • Average Cash & Equivalents over 5 years is $29.7 million, with a median of $27.5 million recorded in 2023.
  • Year-over-year, Cash & Equivalents surged 189.46% in 2021 and then plummeted 82.1% in 2025.
  • Traws Pharma's Cash & Equivalents stood at $55.1 million in 2021, then decreased by 29.62% to $38.8 million in 2022, then tumbled by 46.28% to $20.8 million in 2023, then rose by 2.48% to $21.3 million in 2024, then tumbled by 82.1% to $3.8 million in 2025.
  • According to Business Quant data, Cash & Equivalents over the past three periods came in at $3.8 million, $6.4 million, and $13.1 million for Q4 2025, Q3 2025, and Q2 2025 respectively.